DEA Yanks Doctor's Controlled Substance License in Two States
Published Date: 10/20/2025
Notice
Summary
Dr. Chantal F. Nouvellon's DEA registrations to handle controlled substances are being revoked because she no longer has permission to do so in Massachusetts and New Hampshire. She didn’t ask for a hearing, so the DEA is moving forward with the revocation. This means she must stop handling controlled substances immediately, affecting her medical practice and registration status.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registrations Revoked; Stop Controlled Substances
Dr. Chantal F. Nouvellon's two DEA certificates (Nos. BN5595775 and FN5439016) are revoked and she must stop handling controlled substances immediately. The Order is effective November 19, 2025.
Pending Registration Applications Denied in MA & NH
The Order denies any pending applications by Chantal F. Nouvellon to renew or modify DEA registrations, and denies any pending applications for additional registration in Massachusetts or New Hampshire. This denial is effective November 19, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-19599, Ali Elhorr, M.D.; Decision and Order
Dr. Ali Elhorr from Michigan tried to get a DEA registration but got denied because he’s banned from federal health programs and lied on his application. He didn’t respond to the government’s requests, so the denial is final. This means he can’t legally prescribe controlled substances, affecting his medical practice and income starting now.
Next: 2025-19601, Debt Management Advisory Committee Meeting
On November 4, 2025, the Treasury’s Debt Management Advisory Committee will meet behind closed doors to give expert advice on managing the nation’s debt and financial plans. This meeting affects the government’s borrowing strategies and could influence how the Treasury handles money and debt in the future. While the public won’t see the discussions, the committee’s recommendations will help shape important financial decisions.